CN101965347B - 作为激酶抑制剂的吡唑并吡啶 - Google Patents

作为激酶抑制剂的吡唑并吡啶 Download PDF

Info

Publication number
CN101965347B
CN101965347B CN2009801083206A CN200980108320A CN101965347B CN 101965347 B CN101965347 B CN 101965347B CN 2009801083206 A CN2009801083206 A CN 2009801083206A CN 200980108320 A CN200980108320 A CN 200980108320A CN 101965347 B CN101965347 B CN 101965347B
Authority
CN
China
Prior art keywords
hydrogen
compound according
mmol
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801083206A
Other languages
English (en)
Chinese (zh)
Other versions
CN101965347A (zh
Inventor
詹姆斯·布拉克
英德拉尼·W·古纳沃达纳
伊范·勒许罗
彼得·J·莫尔
伊莱·M·华莱士
王斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101965347A publication Critical patent/CN101965347A/zh
Application granted granted Critical
Publication of CN101965347B publication Critical patent/CN101965347B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801083206A 2008-01-09 2009-01-08 作为激酶抑制剂的吡唑并吡啶 Expired - Fee Related CN101965347B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1986508P 2008-01-09 2008-01-09
US61/019,865 2008-01-09
PCT/US2009/030450 WO2009089359A1 (en) 2008-01-09 2009-01-08 Pyrazolopyridines as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101965347A CN101965347A (zh) 2011-02-02
CN101965347B true CN101965347B (zh) 2013-01-02

Family

ID=40351716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801083206A Expired - Fee Related CN101965347B (zh) 2008-01-09 2009-01-08 作为激酶抑制剂的吡唑并吡啶

Country Status (7)

Country Link
US (1) US8372842B2 (2)
EP (1) EP2242757B1 (2)
JP (2) JP5608098B2 (2)
CN (1) CN101965347B (2)
CA (1) CA2711741A1 (2)
ES (1) ES2392014T3 (2)
WO (1) WO2009089359A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459046B (zh) * 2014-06-17 2019-01-08 Ucb生物制药私人有限公司 作为激酶抑制剂的吡唑并吡啶衍生物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711614A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
AU2013216354B2 (en) * 2012-02-02 2017-08-31 Idorsia Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
SG11201406818VA (en) 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
CN104119331B (zh) * 2013-04-26 2018-02-06 广东东阳光药业有限公司 烯基化合物及其使用方法和用途
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN105705499B (zh) 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067123B1 (en) 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
AU2003230367A1 (en) * 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
AU2004272437A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EP2354140A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2006130673A1 (en) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
WO2007059219A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
JP2009534454A (ja) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
US8618121B2 (en) * 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
CA2711614A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CN101970415A (zh) 2008-01-09 2011-02-09 阵列生物制药公司 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
JP5805071B2 (ja) 2009-04-11 2015-11-04 アレイ バイオファーマ、インコーポレイテッド Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gary T. Wang,et al.,.1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyano-pyrazi-2-yl)ureas as Potent and Selective Inhibitors of Chk1 Kinase:Synthesis,Preliminary SAR,and Biological Activities.《Journal of Medicinal Chemistry》.2005,第48卷(第9期),3118-3121. *
Kenneth L.Arrington,et al.,.Novel Inhibitors of Checkpoint Kinase 1.《ChemMedChem》.2007,第2卷(第11期),1571-1585. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459046B (zh) * 2014-06-17 2019-01-08 Ucb生物制药私人有限公司 作为激酶抑制剂的吡唑并吡啶衍生物

Also Published As

Publication number Publication date
CA2711741A1 (en) 2009-07-16
JP5608098B2 (ja) 2014-10-15
US8372842B2 (en) 2013-02-12
EP2242757A1 (en) 2010-10-27
US20100280043A1 (en) 2010-11-04
CN101965347A (zh) 2011-02-02
WO2009089359A1 (en) 2009-07-16
ES2392014T3 (es) 2012-12-03
JP2011509302A (ja) 2011-03-24
JP2014129379A (ja) 2014-07-10
EP2242757B1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
CN101965347B (zh) 作为激酶抑制剂的吡唑并吡啶
CN101959887B (zh) 作为激酶抑制剂的吡咯并吡啶
CN103958479B (zh) 吡唑并喹啉酮衍生物、其制备和其治疗用途
EP1658289B1 (en) 3-substituted imidazopyridine-derivatives as c-kit inhibitors
CN103260622B (zh) 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物
CN112135824A (zh) 作为免疫调节剂的杂环化合物
TWI697490B (zh) 用於作為shp2抑制劑之新穎雜環衍生物
CN105120862A (zh) Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
CN101389324A (zh) Aurora激酶的氮杂吲哚抑制剂
CN113316576A (zh) 用于治疗癌症的作为HPK1抑制剂的2,3-二氢-1H-吡咯并[3,4-c]吡啶-1-酮衍生物
TW201020253A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
CN104011052A (zh) 新的化合物
WO2025011480A1 (zh) 化合物及其作为抗癌药的用途
WO2018108079A1 (zh) 多激酶抑制剂化合物、其晶型及用途
CN105408321A (zh) 新的吲哚和吡咯衍生物、它们的制备方法和含有它们的药物组合物
CN105431422A (zh) 新的异吲哚啉或异喹啉化合物、其制备方法以及含有它们的药用组合物
WO2017101796A1 (zh) 酞嗪酮衍生物、其制备方法及用途
WO2020143763A1 (zh) 卤代烯丙基胺类化合物及其应用
CN110267959A (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
WO2022148196A1 (zh) 多激酶抑制剂及其用途
TW202321232A (zh) 小分子sting拮抗劑
US20140221370A1 (en) Pyrrolopyridines as kinase inhibitors
CN118791465A (zh) Cbl-b抑制剂
HK40105393A (zh) Sting(干扰素基因刺激剂)的调节剂
HK1144423A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130102

Termination date: 20160108